close
close

Outset Medical (OM) faces investor scrutiny after FDA warning letter leads to poor financial results – Hagens Berman

Posted on by Vaseline
Outset Medical (OM) faces investor scrutiny after FDA warning letter leads to poor financial results – Hagens Berman

OM encourages investors with losses to contact the company

San Francisco, California–(Newsfile Corp. – September 11, 2024) – Hagens Berman Encourages Outset Medical (NASDAQ: OM) investors who have suffered significant losses to file your losses now. The company also encourages persons with knowledge who can assist the investigation to contact its attorneys.

Related Posts